17 research outputs found
Nitric oxide produces HLA-G nitration and induces metalloprotease-dependent shedding creating a tolerogenic milieu
Human leucocyte antigen G (HLA-G) is a tolerogenic molecule that protects the
fetus from maternal immune attack, may favour tumoral immunoescape and is
up-regulated in viral and inflammatory diseases. The aim of this work was to
discover if nitric oxide (NO) could affect HLA-G expression or function because
NO is an important modulator of innate and adaptive immunity. For this purpose
HLA-G expression and function were analysed following treatment with a NO donor
or a peroxynitrite donor in various cell lines expressing HLA-G either
spontaneously or upon transfection. Results showed NO-dependent nitration of both
cellular and soluble HLA-G protein, but not all HLA-G moieties underwent
nitration. Endogenous biosynthesis of NO by both U-937-HLA-G1 and M8-HLA-G5
stable transfectants also caused HLA-G nitration. The NO decreased total HLA-G
cellular protein content and expression on the cell surface, while increasing
HLA-G shedding into the culture medium. This effect was post-transcriptional and
the result of metalloprotease activity. By contrast, NO pretreatment did not
affect HLA-G capability to suppress NK cytotoxicity and lymphocyte proliferation.
Our studies show that NO regulates the availability of HLA-G molecules without
modifying their biological activities
Linking Two Immuno-Suppressive Molecules: Indoleamine 2,3 Dioxygenase Can Modify HLA-G Cell-Surface Expression1
Nonclassical human leukocyte antigen (HLA) class I molecule
HLA-G and indoleamine 2,3 dioxygenase (INDO) in humans and
mice, respectively, have been shown to play crucial immunosuppressive
roles in fetal-maternal tolerance. HLA-G inhibits
natural killer and T cell function by high-affinity interaction with
inhibitory receptors, and INDO acts by depleting the surrounding
microenvironment of the essential amino acid tryptophan,
thus inhibiting T cell proliferation. We investigated whether
HLA-G expression and INDO function were linked. Working
with antigen-presenting cell (APC) lines and monocytes, we
found that functional inhibition of INDO by 1-methyl-tryptophan
induced cell surface expression of HLA-G1 by HLA-G1-
negative APCs that were originally cell-surface negative, and
that in reverse, the functional boost of INDO by high concentrations
of tryptophan induced a complete loss of HLA-G1 cell
surface expression by APCs that were originally cell-surface
HLA-G1-positive. This mechanism was shown to be posttranslational
because HLA-G protein cell contents remained unaffected
by the treatments used. Furthermore, HLA-G cell surface
expression regulation by INDO seems to relate to INDO function,
but not to tryptophan catabolism itself. Potentia
Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors
The non-classical Human leukocyte antigen G (HLA-G) differs from classical HLA class I molecules by its low genetic diversity, a tissue-restricted expression, the existence of seven isoforms, and immuno-inhibitory functions. Most of the known functions of HLA-G concern the membrane-bound HLA-G1 and soluble HLA-G5 isoforms, which present the typical structure of classical HLA class I molecule: a heavy chain of three globular domains α(1)-α(2)-α(3) non-covalently bound to β-2-microglobulin (B2M) and a peptide. Very little is known of the structural features and functions of other HLA-G isoforms or structural conformations other than B2M-associated HLA-G1 and HLA-G5. In the present work, we studied the capability of all isoforms to form homomultimers, and investigated whether they could bind to, and function through, the known HLA-G receptors LILRB1 and LILRB2. We report that all HLA-G isoforms may form homodimers, demonstrating for the first time the existence of HLA-G4 dimers. We also report that the HLA-G α(1)-α(3) structure, which constitutes the extracellular part of HLA-G2 and HLA-G6, binds the LILRB2 receptor but not LILRB1. This is the first report of a receptor for a truncated HLA-G isoform. Following up on this finding, we show that the α(1)-α(3)-Fc structure coated on agarose beads is tolerogenic and capable of prolonging the survival of skin allografts in B6-mice and in a LILRB2-transgenic mouse model. This study is the first proof of concept that truncated HLA-G isoforms could be used as therapeutic agents
Hla-g expression levels influence the tolerogenic activity of human DC-10
Human leukocyte antigen (HLA)-G is a non-classical HLA class I molecule with known immune-modulatory functions. Our group identified a subset of human dendritic cells, named DC-10, that induce adaptive interleukin-10-producing T regulatory type 1 (Tr1) cells via the interleukin-10-dependent HLA-G/ILT4 pathway. In this study we aimed at defining the role of HLA-G in DC-10-mediated Tr1 cell differentiation. We analyzed phenotype, functions, and genetic variations in the 3’ untranslated region of the HLA-G locus of in vitro-differentiated DC-10 from 67 healthy donors. We showed that HLA-G expression on DC-10 is donor-dependent. Functional studies demonstrated that DC-10, independently of HLA-G expression, secrete interleukin-10 and negligible levels of interleukin-12. Interestingly, DC-10 with high HLA-G promote allo-specific anergic T cells that contain a significantly higher frequency of Tr1 cells, defined as interleukin-10-producing (P=0.0121) or CD49b+LAG-3+(P=0.0031) T cells, compared to DC-10 with low HLA-G. We found that the HLA-G expression on DC-10 is genetically imprinted, being associated with specific variations in the 3’ untranslated region of the gene, and it may be finely tuned by microRNA-mediated post-transcriptional regulation. These data highlight the important role of HLA-G in boosting DC-10 tolerogenic activity and confirm that interleukin-10 production by DC-10 is necessary but not sufficient to promote Tr1 cells at high frequency. These new insights into the role of HLA-G in DC-10-mediated induction of Tr1 cells provide additional information for clinical use in Tr1-or DC-10-based cell therapy approaches
Multiplex bead-based immunoassay for the free soluble forms of the HLA-G receptors, ILT2 and ILT4
Nitric oxide produces HLA-G nitration and induces metalloprotease-dependent shedding creating a tolerogenic milieu
Human leucocyte antigen G (HLA-G) is a tolerogenic molecule that protects the
fetus from maternal immune attack, may favour tumoral immunoescape and is
up-regulated in viral and inflammatory diseases. The aim of this work was to
discover if nitric oxide (NO) could affect HLA-G expression or function because
NO is an important modulator of innate and adaptive immunity. For this purpose
HLA-G expression and function were analysed following treatment with a NO donor
or a peroxynitrite donor in various cell lines expressing HLA-G either
spontaneously or upon transfection. Results showed NO-dependent nitration of both
cellular and soluble HLA-G protein, but not all HLA-G moieties underwent
nitration. Endogenous biosynthesis of NO by both U-937-HLA-G1 and M8-HLA-G5
stable transfectants also caused HLA-G nitration. The NO decreased total HLA-G
cellular protein content and expression on the cell surface, while increasing
HLA-G shedding into the culture medium. This effect was post-transcriptional and
the result of metalloprotease activity. By contrast, NO pretreatment did not
affect HLA-G capability to suppress NK cytotoxicity and lymphocyte proliferation.
Our studies show that NO regulates the availability of HLA-G molecules without
modifying their biological activities
Linking Two Immuno-Suppressive Molecules: Indoleamine 2,3 Dioxygenase Can Modify HLA-G Cell-Surface Expression 1
ABSTRAC